

# A bacterial regulatory RNA attenuates virulence, spread and human host cell phagocytosis

Hélène Le Pabic, Noëlla Germain-Amiot<sup>†</sup>, Valérie Bordeau<sup>†</sup> and Brice Felden<sup>\*</sup>

Inserm U835-Upres EA2311, Biochimie Pharmaceutique, Rennes University, 2 av. du prof. Léon Bernard, 35000 Rennes, France

Received December 03, 2014; Revised July 20, 2015; Accepted July 21, 2015

## ABSTRACT

***Staphylococcus aureus* pathogenesis is directed by regulatory proteins and RNAs. We report the case of an RNA attenuating virulence and host uptake, possibly to sustain commensalism. A *S. aureus* sRNA, SprC (srn\_3610), reduced virulence and bacterial loads in a mouse infection model. *S. aureus* deleted for *sprC* became more virulent and increased bacterial dissemination in colonized animals. Conversely, inducing SprC expression lowered virulence and the bacterial load. Without *sprC*, *S. aureus* phagocytosis by monocytes and macrophages was higher, whereas bacteria were internalized at lower yields when SprC expression was stimulated. Without *sprC*, higher internalization led to a greater number of extracellular bacteria, facilitating colonization. SprC expression decreased after phagocytosis, concurring with the facilitated growth of bacteria lacking the sRNA in the presence of an oxidant. The major staphylococcal autolysin facilitates *S. aureus* uptake by human phagocytes. ATL proved to be negatively regulated by SprC. The SprC domains involved in pairing with *atl* mRNA were analyzed. The addition of ATL reduced phagocytosis of bacteria lacking *sprC* with no effects on wild-type bacterial uptake, implying that SprC influences phagocytosis, at least in part, by controlling ATL. Since the control of SprC on ATL was modest, other factors must contribute to *atl* regulation.**

## INTRODUCTION

Infected hosts sense the presence of pathogens and activate immune defense mechanisms for survival. The immune system relies on antimicrobial peptides, lytic enzymes, complement activation and phagocyte recruitment. Upon interaction of bacteria with host cell receptors, the host cells protect and repair their DNA, prevent apoptosis and

secrete antimicrobial peptides. Subsequently, the release of adhesins and chemo-attractants leads to phagocyte recruitment at the infection site to trigger an inflammatory response (1). Microorganisms have developed ingenious mechanisms to fight and bypass the host signaling pathways and immune responses for survival and spread into their hosts (2,3).

*Staphylococcus aureus* (*S. aureus*) is a Gram-positive bacterium that rapidly acquires antibiotic resistances, being a worldwide health problem causing nosocomial and community-associated infections. *S. aureus* has surface and secreted components that compromise the host immune response, allowing bacterial escape (4,5). Staphylococcal adherence to the host cells represents a prerequisite for their uptake. *S. aureus* can be internalized and survive in various host cells. This represents a critical factor for persistence and also when infections recidivate (6). The ability of *S. aureus* to escape from the host lysosomal degradation machinery and to persist intracellularly for long time periods is an essential step during infection. If engulfed by neutrophils, the intracellular bacteria can resist reactive oxygen intermediates, nitric oxide radicals, defensins and bactericidal proteins (6). After *S. aureus* internalization in non-phagocytic cells, the host cells up-regulate genes involved in innate immunity, antigen presentation and cell signaling (7). Upon internalization, *S. aureus* also reprograms gene expression (8–10). Bacterial genes involved in capsule synthesis, oxidative stress and virulence are up-regulated following ingestion of the pathogen (7,9). After *S. aureus* uptake by the human lung epithelial cells, bacterial genes involved in cell division and nutrient transport are down-regulated whereas genes involved in iron scavenging and virulence are up-regulated. During infection, *S. aureus* generates many virulence factors whose timing and expression levels are tuned by dozens of regulatory proteins and RNAs (sRNAs). *S. aureus* expresses around 159 sRNAs (11,12) recently compiled into the SRD database (13) with, for the most part, no associated functions. These sRNAs are expressed from the core and variable accessory genome including Pathogenicity Islands and transposons (14). Some sRNAs either stimulate

<sup>\*</sup>To whom correspondence should be addressed. Tel: +33 2 23234851; Fax: +33 2 23234456; Email: bFelden@univ-rennes1.fr

<sup>†</sup>These authors contributed equally to the paper.

(15) or decrease (16) bacterial virulence in animal models of infection and others influence antibiotic resistance (17).

In this report, we provide evidence that the Small pathogenicity island *rna C*, SprC, alias *srn\_3610* (13), when expressed by a *S. aureus* strain isolated from a human infection, diminishes bacterial virulence and spread in an animal model of septicemia. An isogenic strain lacking *sprC* becomes more virulent and complementation of the sRNA restores a lower virulence phenotype. SprC also reduces *S. aureus* phagocytosis by human monocytes and macrophages. The sRNA disfavors bacterial resistance to an oxidative stress, concurrent with extinction of SprC expression after host cell uptake. The staphylococcal autolysin (ATL) functions as an adhesin/invasin and binds the heat shock cognate protein Hsc70 host cellular receptor (18). At the molecular level, SprC interacts with the *atl* mRNA, in turn inhibiting ATL expression through a direct pairing interaction between SprC and the *atl* mRNA. The SprC phagocytosis phenotype is mediated, at least in part, by ATL. Overall, SprC attenuates bacterial virulence and host cell phagocytosis. It suggests that this regulatory RNA, when expressed, may favor commensalism with the host.

## MATERIALS AND METHODS

### Strains, culture conditions, genetic manipulations and oxidative stress experiments

All the bacterial strains and plasmids used are listed in Supplementary Table S1. *S. aureus* strains were grown at 37°C in brain heart infusion broth (BHI, Oxoid). When necessary, chloramphenicol and erythromycin were added at a 10 µg/ml concentration. For the oxidative stress, overnight cultures were diluted (1/100), incubated with 5 mM hydrogen peroxide (Aldrich Chemical, St Louis, MO) and optical density was measured using the spectrophotometer Biotek Synergy 2. A chromosomal gene disruption mutant was constructed by deletion of the targeted gene and insertion of an erythromycin-resistance gene by using the temperature-sensitive vector pBT2 (19) according to (15). Double-crossover events corresponding to the desired gene disruptions were confirmed by polymerase chain reaction (PCR) and sequenced. In all the sRNA overexpression genetic constructions, the RNAs are expressed from their endogenous promoters. In pCN35Ω*sprC* and pCN38Ω*sprC*, the nucleotide sequence of *sprC* containing 300 upstream nucleotides was amplified from Newman genomic DNA as a 460-bp fragment possessing EcoRI and PstI restriction sites at each end. The PCR product was cloned in pCN35erm and pCN38cat. *E. coli* DH5α were transformed with pCN35Ω*sprC* and pCN38Ω*sprC* and selected for ampicillin resistance. The plasmids pCN35-*sprC* and pCN38-*sprC* were transferred into RN4220 and selected for erythromycin and chloramphenicol resistance respectively, then finally transferred to Newman WT and Newman Δ*sprC*.

### *S. aureus* FITC labeling and microscopy

Bacteria were labeled with fluorescein isothiocyanate (FITC) for the phagocytosis assay. 50 ml of cultured cells

(mid-log phase, OD<sub>600nm</sub> = 2) were harvested by centrifugation. The cell pellet was washed with phosphate-buffered saline (PBS) and re-suspended in 1 ml of carbonate/bicarbonate buffer (pH 9.5, 0.1 M Na<sub>2</sub>CO<sub>3</sub> and 0.2 M NaHCO<sub>3</sub>). The FITC (Sigma Chemical Co., St. Louis, Mo.) was dissolved in dimethyl sulfoxide at 10 mg/ml. 100 µl of this solution was added to 500 µl of the bacterial suspension. The mixture was rotated at 180 rpm for 1 h at room temperature. Bacteria were then washed twice in PBS to remove the unbound fluorochrome and re-suspended in 500 µl of HBSS (Hanks Balanced Salt Solution). Aliquots were prepared, frozen and stored in the dark until used. Aliquots were thawed just before use. Dilutions of stock suspensions of FITC-labeled bacteria or control bacteria were plated on agar to determine the number of CFU/ml. Coverslips were mounted with Vectashield mounting medium including DAPI (Vector Laboratories, Burlingame, CA). Staining was viewed with an inverted confocal microscope (DMIRE2, Leica) equipped with a 63XNA 1.4 objective lens using the LS 3D software (Leica). Images were analyzed using the 'MetaMorph' (Molecular Devices, Downingtown, PA) and Volocity (Perkin Elmer, version 6.0.1) software.

### Human macrophages production

THP1 human monocytes were obtained from ATCC (Rockville, MD) and maintained at 37°C with 5% CO<sub>2</sub> in RPMI 1640 (Invitrogen, Carlsbad, USA) containing 10% FCS (Biowest). The THP1 cells were treated with PMA (20 ng/ml) (Sigma) for 3 days to stimulate their differentiation into macrophages. The THP1 monocytes were efficiently differentiated into adherent macrophages, as evidenced by light microscopy.

### Samples preparation, flow cytometry and phagocytosis assays in the human THP1 and macrophages

Human THP1 cells (10<sup>6</sup> cells) were incubated with 10<sup>7</sup> bacteria in RPMI, 10% human serum AB (SAB) (Institut Jacques Boy, Reims, France) to stimulate opsonization, for different times, as indicated, at 37°C, 180 rpm. The extracellular bacteria were lysed by lysostaphin (10 µg/ml) for 10 min and the cells were washed with RPMI, 10% SAB and with PBS. At the indicated time points, the THP1 cells containing intracellular *S. aureus* were lysed for total RNA extraction. The cells were fixed in PBS / 4% paraformaldehyde and analyzed using a FC500 flow cytometer and CXP Analysis Software (Beckman Coulter, Villepinte, France). To quantify bacterial phagocytosis, the human THP1 macrophages were infected with *S. aureus* at a multiplicity of infection (MOI) of 1:25. Phagocytosis assays were carried out for 2 h at 37°C, in the presence of 5% CO<sub>2</sub> in RPMI 1640 medium containing 10% human SAB. Phagocytosis was stopped by putting the plates on ice and washing the cells three times with ice-cold PBS. All the non-phagocytosed bacteria were killed by culturing the human cells for 24 h in a medium containing 50 µg/ml gentamycin (Sigma). Subsequently, the medium was removed from each well and the cells were washed three times with PBS and incubated with PBS/SDS 0.1% for 15 min to lyse the cells.

The lysates were plated in various dilutions on BHI agar plates. The colony counts were performed to determine the number of intra- and extracellular bacteria. All the samples were prepared and tested in triplicate. For the inhibition of phagocytosis mediated by ATL, the macrophages were pre-incubated with ATL in a concentration range of 5 to 50 nM for 30 min at 37°C, 5% CO<sub>2</sub> prior to the infection with a *S. aureus* strain lacking *sprC* expression (Newman  $\Delta sprC$ ).

#### Cytochalasin D treatment and intracellular bacteria counting

To study the role of the human cell cytoskeleton in *S. aureus* uptake and provide evidence for phagocytosis, human THP1 macrophages were incubated with 2.5 and 5  $\mu\text{g/ml}$  cytochalasin D (Sigma) for 60 min at 37°C before *S. aureus* interaction and also during the experiment. Human THP1 macrophages were infected with *S. aureus* and phagocytosis was carried out for 2 h at 37°C, 5% CO<sub>2</sub>, in RPMI 1640 medium. Phagocytosis was stopped by putting the plates on ice and washing the cells three times with ice-cold PBS. The remaining non-phagocytosed bacteria were killed by adding 100  $\mu\text{g/ml}$  gentamycin (Sigma) and cytochalasin D (1 to 2.5  $\mu\text{g/ml}$ , Sigma) in the medium for 60 min, at 37°C, 5% CO<sub>2</sub>. Subsequently, the medium was removed from each well, the cells were washed with PBS and cold distilled water was added to lyse the cells by repeated pipetting. The lysates were plated, in various dilutions, on BHI agar plates and incubated overnight at 37°C to determine the number of intracellular bacteria.

#### RNA extractions, Northern blots, reverse transcription and qPCR assays

Isolated colonies were suspended in BHI and incubated at 37°C overnight. The culture was diluted 1:100 then incubated at 37°C with agitation and stopped at various phases of growth. RNA extraction was performed as described (20). The DNA probes used to detect sRNA are listed in Supplementary Table S2. Total RNA (10  $\mu\text{g}$ ) was separated on denaturing 6% PAGE and transferred onto a Zeta probe GT membrane (Bio-Rad) in 0.5 $\times$  TBE. The membranes were hybridized with specific <sup>32</sup>P-labeled probes in ExpressHyb solution (Clontech), washed, exposed and scanned with a PhosphorImager (Molecular Dynamics). Contaminating DNA was removed from RNA samples by treatment with DNase (DNase amplification grade, Invitrogen, Carlsbad, USA) according to the manufacturer's protocol. Two micrograms of RNA was used for first strand cDNA synthesis using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, USA) following the manufacturer's protocols. Real-time quantitative PCR was performed with the fluorescent dye SYBR Green methodology using the Real Master Mix (Eppendorf) and the Mastercycler realplex (Eppendorf). Supplementary Table S3 shows primer pairs for each transcript chosen with the Primer 3 program ([http://frodo.wi.mit.edu/cgi-bin/primer3/primer3\\_www.cgi](http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)). Gene specificity of each pair of primers was checked by comparing their sequences to the GenBank database using the program BLASTN (<http://www.ncbi.nlm.nih.gov/BLAST/>). Using the comparative Ct method, the amount of target sequence in unknown samples was normalized to Hu or 16S reference.

#### Protein isolation, mass spectrometry and immunoblots

For the preparation of the protein extracts, bacteria were grown until the exponential or stationary phases and the cells are pelleted for 10 min at 4°C (8000g). To purify the extracellular proteins, the supernatants were collected and precipitated with 10% trichloroacetic acid. The precipitates were washed with ice-cold acetone and loaded onto SDS-PAGE gels according to (21) and stained with Coomassie blue R-250. The proteins of interest were extracted from the gel, digested with trypsin and the peptides identified by MALDI MS/MS and RP-HPLC/NanoLC/ESI-MS-MS. For the total protein extractions, pellets of 2-ml cultures were washed with TE (50 mM EDTA, 50 mM Tris pH 7.5), and suspended in 0.2 ml of the same buffer containing 0.1 mg/ml lysostaphin. Following incubation at 37°C for 10 min, the samples are boiled for 5 min and analyzed by SDS-PAGE. For the immunoblots, proteins were transferred to PVDF membranes (Immobilon-P, Millipore) and incubated with polyclonal anti-autolysin antibodies (a gift from Dr Sugai, Hiroshima University, Japan, (22)). Signals were visualized using a STORM 840 Phosphor-Imager (Molecular Dynamics).

#### Toeprints and gel retardation assays

Annealing mixtures containing 0.15 pmol of unlabeled *atl*<sub>154</sub> mRNA (154 nts, including the mRNA 5'-UTR, starting with three additional Gs for transcriptional efficiency) and 1.5 pmol of labeled primer in 20 mM Tris-acetate (pH 7.5), 60 mM NH<sub>4</sub>Cl and 1 mM DTT were incubated for 1 min at 90°C and quickly chilled on ice for 1 min. Renaturation proceeded in 10 mM MgCl<sub>2</sub> at 20°C for 15 min. The influence of SprC (a 150 nt-long synthetic transcript with 3 additional Gs at the 5'-end for transcription efficiency), SprC $\Delta_{78-89}$  (a 138 nt-long RNA) or SprC $\Delta_{55-67}$  (a 137 nt-long RNA) was assayed by adding increasing amounts of each RNA (7.5 to 30 pmol) to the annealing mixtures and incubating for 5 min at 37°C. The purified *E. coli* 70S ribosomes was diluted in the reaction buffer in the presence of 1 mM MgCl<sub>2</sub>, and then activated for 15 min at 37°C. For each sample, 0.3 pmol of 70S ribosomes was added, followed by 5 min incubation at 37°C and adjustment of the MgCl<sub>2</sub> concentration to 10 mM. After 10 min at 37°C, 10 pmol of uncharged tRNA<sup>Met</sup> were added and the samples incubated for 5 min at 37°C. The cDNAs were synthesized using three units of AMV RT (New England Biolabs, Ipswich, USA) for 15 min at 43°C. Reactions were stopped by adding 10  $\mu\text{l}$  of loading buffer II (Ambion, Foster City, USA). The cDNAs were loaded and separated on a urea 8% PAGE gel. The toeprint position on *atl*<sub>154</sub> mRNA was determined by DNA sequencing. The results were analyzed on a PhosphorImager. For the electrophoretic mobility shift assays, the *atl*<sub>154</sub> mRNA with SprC or SprC $\Delta_{78-89}$ , or SprC $\Delta_{55-67}$  RNAs were denatured in 80 mM Hepes (pH 7.5), 330 mM KCl and 4 mM MgCl<sub>2</sub> for 2 min at 80°C, chilled on ice and refolded for 20 min at 20°C. For the binding reaction (10  $\mu\text{l}$  reaction volume), the incubation was for 30 min at 30°C. 0.005 pmol of labeled *atl*<sub>154</sub> mRNA was incubated with 6 to 200 pmol of unlabeled SprC for Kd determination, or with the mutants from 5 to 40 pmol. To demonstrate specificity, 250 or 500 pmol of unlabeled SprA<sub>2AS</sub> were added. The

samples were supplemented with 10% glycerol (final concentration) and loaded on a native 8% polyacrylamide gel containing 5% glycerol. The electrophoresis was performed in 0.5X Tris-borate EDTA at 4°C (100V). The results were analyzed on a PhosphorImager.

### Filter binding assays

0.5 pmol of labeled *atl*<sub>154</sub> mRNA or SprC were incubated in 20 mM Tris-acetate (pH 7.5), 60 mM NH<sub>4</sub>Cl, 1 mM DTT for 1 min at 90°C and chilled on ice for 1 min. Renaturation was performed in 10 mM MgCl<sub>2</sub> at 20°C for 15 min. Purified *E. coli* 70S ribosomes were diluted in the reaction buffer in the presence of 1 mM MgCl<sub>2</sub> and activated for 15 min at 37°C. For the samples containing 70S ribosomes, 5 pmol of 70S ribosomes were added, followed by 5 min incubation at 37°C and the concentration of MgCl<sub>2</sub> adjusted to 10 mM. After 10 min at 37°C, 25 pmol of uncharged tRNA<sup>fMet</sup> were added and the samples incubated for 15 min at 37°C. The final volume was set to 20 μl. For the binding assays, we used nitrocellulose membranes (AppliChem, Pure Nitrocellulose). After equilibrating the membrane with 50 μl of reaction buffer per well, the samples were loaded into the well and sucked through. We washed twice with 50 μl reaction buffer and air-dried the membrane prior exposition onto a phosphor imaging device. The results were analyzed on a PhosphorImager.

### ATL protein purification

A plasmid encoding the 6XHis-fusion ATL protein was a gift from Dr C. Heilmann (Münster University, Germany). Purification of the 6XHis-fusion ATL protein from an *E. coli* culture containing plasmid pQatl was performed under denaturing conditions. Its production, in *E. coli*, was induced by supplementing the culture with 1 mM IPTG during 3 h. The cell pellets were dissolved in a lysis buffer (100 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM Tris-HCl, 8 M Urea, pH 8) and centrifuged. Supernatant fluid was loaded onto an 'AKTA purifier' (GE Healthcare) equipped with a Ni<sup>2+</sup> column. The washes were performed with a buffer containing 100 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM Tris-HCl and 8 M Urea, pH 6.3. The ATL protein was eluted with a buffer containing 100 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM Tris-HCl, 8 M Urea, pH 5.9 and then with the same elution buffer at pH 4.5. ATL was additionally purified under native conditions. The 6XHis-fusion ATL protein was dialyzed against dialysis buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 300 mM NaCl, pH 8) and loaded onto an 'AKTA purifier' equipped with a Ni<sup>2+</sup> column. The washes and binding were performed with a buffer containing 500 mM NaCl, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 5 mM Tris-HCl and 5 mM Imidazole, pH 8. The ATL protein was eluted with a buffer containing 500 mM NaCl, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 5 mM Tris-HCl, 250 mM Imidazole, pH 8. The fractions containing the overexpressed His-tagged ATL were pooled and dialyzed against 50 mM Tris-HCl pH 7.2. The purity of the protein was verified by 10% SDS-PAGE and its concentration estimated with a Qubit fluorometer (Invitrogen).

### Animal infection experiments

Experiments were monitored in the central animal laboratory ARCHE-BIOSIT- Rennes and all protocols were approved by the ethics committee (agreement No. R-2011-PT-01). Virulence levels of strain Newman, its isogenic deletion mutant  $\Delta$ *sprC*-pCN38 and the complemented strain  $\Delta$ *sprC*-pCN38 $\Omega$ *sprC* were compared using a murine intravenous sepsis model. Groups of 10 female Swiss mice, 6- to 8-weeks old (Janvier Laboratories, Le Genest Saint Isle, France) were inoculated intravenously with 200 μl of bacterial suspensions containing  $5 \times 10^7$  *S. aureus* cells in 0.9% NaCl. The survival of the mice was monitored for 14 days and the statistical significance of differences between groups was evaluated using the Mantel-Haenszel test. A *P*-value <0.05 was considered significant. Four days after inoculation, mice were euthanized with CO<sub>2</sub> and their kidneys excised. After photographs were taken, the organs were homogenized, diluted in 0.9% NaCl and plated on BHI agar for determination of bacterial titers, expressed as log<sub>10</sub> CFU per pair of kidneys. The statistical significance of differences between groups was evaluated using the Mann-Whitney U test. A *P*-value <0.05 was considered significant. The stability of plasmid  $\Delta$ *sprC*-pCN38 $\Omega$ *sprC* (encoding chloramphenicol resistance) in the complemented  $\Delta$ *sprC* mutant was assessed by plating randomly selected colonies grown from kidney homogenates on nutrient agar containing chloramphenicol.


### Statistical analysis of the data

For the statistical analysis of the data, the Mann-Whitney and Wilcoxon (animal infection experiments) tests were performed, as indicated for each set of experiments (Figure legends), on at least three independent experiments, to evaluate significance. The data were expressed as mean  $\pm$  standard deviations (SD).

## RESULTS

### SprC negatively controls the expression of the major autolysin ATL in *S. aureus*

In a large-scale analysis of the *S. aureus* transcriptome, we identified a small RNA, SprC (srn\_3610, SRD database, (13)), expressed from the genome of a converting phage (14). We determined the 5'- and 3'-ends of SprC by RACE (Rapid Amplification of cDNA Ends) mapping. They were located, respectively, at positions 1918280 and 1918432 within the *S. aureus* Newman sequence. In strain Newman, *sprC* is located in the  $\nu$ SA $\beta$  pathogenicity island (PI) that contains several virulence factors (14). Another *S. aureus* sRNA, SprD, also situated within a PI, has a positive role on virulence (15). According to the location of *sprC* within a PI, we postulated that it could also be involved in staphylococcal pathogenesis. In order to identify molecular targets of SprC, we analyzed whether the sRNA modifies the expression of the extracellular proteins that include virulence factors, as reported (15). To achieve this goal, a *sprC* deletion mutant was constructed by homologous recombination in strain Newman, isolated from a human infection. Northern blots confirmed the absence of SprC expression



**Figure 1.** *S. aureus* SprC sRNA (srn\_3610) lowers the expression levels of the major autolysin ATL. (A) Monitoring the bacterial growth and SprC expression levels, by Northern blots (OD<sub>600nm</sub>: 2), in *S. aureus* strains Newman (blue diamonds), Newman- $\Delta$ sprC (pink rectangles). (B) Monitoring the

in strain Newman- $\Delta sprC$  and the growth curves of strains Newman and Newman- $\Delta sprC$  were identical (Figure 1A). Overexpression of SprC was achieved using a 'multicopy' plasmid expressing SprC from its endogenous promoter, with no impact on cell growth (pCN38- $\Omega sprC$ , Figure 1B).

In the extracellular proteins extracted from strain Newman-pCN38 $\Omega sprC$ , levels of an ~85 kD protein decreased as compared to the isogenic Newman strain (Figure 1C, arrow). Proteins from that band were eluted, tryptic digests were prepared and the fragments analyzed by MALDI-TOF mass spectrometry. Twenty-three peptides were identified (Table 1), all matching the sequence of the major autolysin ATL protein encoded by *atl* (23). The ATL proteins are associated with the bacterial surface by ionic or hydrophobic interactions and have enzymatic (peptidoglycan-hydrolytic) and adhesive functions. The ATL protein is detected within the cytoplasm as well as at the cell surface and extracellularly, after cleavage (22). An independent confirmation of the decrease in the autolysin levels, when SprC expression is induced, was obtained by monitoring the autolysin protein within a total protein extract by immunoblots with anti-autolysin antibodies (Figure 1D). The immunoblots detected five proteins in the cellular extracts, with apparent molecular weights of 138, 115, 85, 62 and 51 kDa (Figure 1D). According to (22), the 138 kDa bi-functional ATL protein contains both the amidase (Ami) and the glucosaminidase (GL) domains that is processed into two intermediates of 115 and 85 kDa, both of which are subsequently cleaved to produce, respectively, an N-terminal amidase domain (Ami, N-acetylmuramoyl-L-alanine amidase; 62 kDa) and a C-terminally located glucosaminidase domain (GL, endo-b-N-acetylglucosaminidase; 51 kDa, (23), that correspond to the two lower bands detected by immunoblots (Figure 1D). As additional and independent experimental evidence of the negative regulation of ATL by SprC, immunoblots performed in strain Newman  $\Delta sprC$  indicated that the expression levels of the ATL protein were increased compared to the isogenic Newman strain (Figure 1E).

#### ATL regulation by SprC is not at the transcriptional level but SprC reduces ATL expression by pairing with the mRNA and preventing ribosome loading

To determine whether ATL regulation by SprC occurs at the transcriptional level, we examined the effect of SprC on the steady-state levels of *atl* mRNA. The *atl* mRNA levels were monitored by quantitative PCR (qPCR), in strains New-


man WT-pCN38 and WT-pCN38 $\Omega sprC$ , using *hu* as a reference gene. The *atl* mRNA expression profile was similar in both strains, elevated early, decreasing at the E phase, rising at the early S phase and decreasing thereafter (Figure 1F). During *S. aureus* growth, the *atl* mRNA expression profile is not influenced by stimulating SprC expression, indicating that SprC induction does not modify the *atl* mRNA steady-state level (Figure 1F). Thus, the regulation of ATL by SprC is not at the mRNA accumulation level, implying that SprC may prevent *atl* mRNA translation.

The above data prompted us to test for the existence of an interaction between SprC and the *atl* mRNA that could reduce the mRNA translation. We did electrophoretic mobility shift assays (EMSA) to analyze duplex formation between SprC and a 154 nt-long *atl* mRNA fragment containing its 5' UTR sequence (34 nt plus 3Gs at the 5'-end), followed by the first 39 codons. SprC formed a specific complex with the *atl*<sub>151</sub> mRNA *in vitro* (Figure 2A, left panel), suggesting that the *atl* mRNA is a direct target of SprC. The estimated Kd between the two RNAs is approximately 35  $\mu$ M, suggesting that additional ligands might be involved in the recognition process between the two RNAs *in vivo*. The binding between SprC and the *atl* mRNA was specific, since a ten-fold excess of an unrelated RNA, SprA2<sub>AS</sub>, was unable to displace SprC from a preformed '*atl* mRNA-SprC' complex (Figure 2A, right panel). SprC secondary structure was inferred by MFold structure prediction (24) and consists of three stem-loops (H1-H3) connected by two single strands (Figure 2B). SprC sequence comparison among the currently published *S. aureus* genomes indicated a ~98% sequence conservation, with two base-pair compensatory changes located within helices H1 and H3, whereas the majority of the other changes are within the predicted RNA single strands (Figure 2B).

We conjectured that SprC could lower ribosome loading to the *atl* mRNA ribosomal binding site (RBS). We tested this hypothesis by performing toeprint analysis. A ternary initiation complex consisting of purified ribosomes, initiator tRNA<sup>fMet</sup> and the *atl* mRNA was formed. The ribosome blocked the elongation of reverse transcription and produced a toeprint 17 nt downstream from the AUG initiation codon of the *atl* mRNA (Figure 2C). SprC reduced the toeprint in a concentration-dependent manner, indicating that SprC inhibits ribosome binding onto the *atl* mRNA RBS. It implies that the pairing interaction between SprC with the *atl* mRNA negatively influences translation initiation. A possible pairing between SprC and

---

bacterial growths and SprC expression levels, by Northern blots (OD<sub>600nm</sub>: 2) of Newman-pCN38 (blue diamonds) and Newman-pCN38 $\Omega sprC$  (pink rectangles). The 5S rRNAs are the loading controls. (C) Coomassie staining of SDS-PAGE of the exoproteins in strain Newman overexpressing (WT-pCN38 $\Omega sprC$ ), or not (WT-pCN38), SprC (OD<sub>600</sub> = 7). The arrows point to the reduced levels of a protein when SprC is overexpressed. (D) Immunoblot analysis with anti-autolysin (anti-ATL) antibodies to monitor the levels of the ATL protein produced as five distinct translational products (23) in strain Newman overexpressing (WT-pCN38 $\Omega sprC$ ), or not (WT-pCN38), SprC. Reduced levels are detected for all the ATL protein products when SprC is overexpressed. Northern blot analyses of SprC expression levels in strains 'WT-pCN38' and 'WT-pCN38 $\Omega sprC$ ' demonstrating SprC overexpression when collecting the exoproteins. 5S rRNAs are the loading controls, 'Spa' corresponds to 'Surface protein A'. (E) Lacking *sprC* increases *S. aureus* ATL expression levels. Immunoblots with anti-ATL antibodies to monitor the expression levels of ATL in *S. aureus* wild type strain (WT) and its isogenic strain lacking *sprC* ( $\Delta sprC$ ). Northern blot analyses of SprC expression levels in strains 'WT' and ' $\Delta sprC$ ' demonstrating the absence of SprC expression in the mutant strain. 5S rRNAs are the loading controls. (F) qPCR analysis of the *atl* mRNA expression levels during bacterial growth in strains Newman 'WT-pCN38' (black bars) and 'WT-pCN38 $\Omega sprC$ ' (white bars). Using the comparative Ct method, the amount of RNAs was normalized against the expression of the *hu* reference gene and referred to the Newman 'WT-pCN38' after 1 h of bacterial growth. The data shown are the mean and the error bars indicated representing Standard Deviation (SD) are derived from three independent experiments.



**Figure 2.** SprC (srn\_3610) interacts with the *atI* mRNA to prevent ribosome loading; SprC secondary structure and SprC mutants enhancing or reducing *atI* mRNA translation initiation. (A) (left panel). Complex formation between an *atI* mRNA fragment and SprC. Native gel retardation assays of purified labeled *atI*<sub>154</sub> mRNA with increasing amounts of purified, unlabeled SprC. (right panel) Competition assays performed with 5 to 10-fold excess of unlabeled, unrelated SprA2 $\Delta\text{S}$  RNA. (B) SprC secondary structure prediction. A careful *sprC* gene sequence comparison among 49 available staphylococcal genomic sequences have evidenced two compensatory base pair changes maintaining base pairings within H1 and H3 (rectangles) and the other nucleotide changes (circles) are located, for the most part, within predicted RNA single strands. The three Gs added at SprC 5'-end for transcription are in italic. (C) (left panel) Toeprint assays on the *atI*<sub>154</sub> mRNA in the presence of increasing concentrations of purified SprC, SprC $\Delta_{55-67}$  or SprC $\Delta_{78-89}$ . '-' indicates the absence of purified 70S ribosomes. The arrow points to the location of the experimentally-determined toeprint. U, A, G and C refer to the *atI* mRNA sequencing ladders. (right panel) Quantitations of the toeprints on the *atI* mRNA in the presence of increasing concentrations of SprC (white), SprC $\Delta_{55-67}$  (black) or SprC $\Delta_{78-89}$  (gray). Without any RNAs, the amount of toeprints was arbitrarily set to 100. The data and error bars, representing SD, indicated are derived from three to six independent experiments. Two and three asterisks corresponded to the *P*-values  $\leq 0.01$  and  $\leq 0.001$ , respectively. (D) Native gel retardation assays of purified labeled *atI*<sub>154</sub> mRNA with increasing amounts of purified, unlabeled SprC or SprC $\Delta_{78-89}$ .

**Table 1.** Mass spectrometry identification of the bi-functional ATL autolysin protein by detecting 23 autolysin peptides

Observed	Mr (expected)	Mr (calculated)	Peptides
1000.5056	999.4984	999.5349	K.DLNVQNLGK.E
1045.5361	1044.5288	1044.5564	K.ASKQQQIDK.S
1151.5647	1150.5574	1150.6023	K.LYTVPWGTSK.Q
1164.5835	1163.5762	1163.5935	K.VTTFASAAQPR.S
1213.5896	1212.5824	1212.6179	K.LYSVWPWGTYK.Q
1310.7420	1309.7348	1309.7466	K.IAQVKPNNTGIR.A
1391.6556	1390.6483	1390.6292	K.IEEDYTSYFPK.Y
1447.6911	1446.6839	1446.6779	K.FYLVQDYNVSGNK.F
1466.7259	1465.7186	1465.7161	K.QVAGSVSGSGNQTFK.A
1671.7965	1670.7892	1670.7801	K.YLGGTDHADPHGYLR.S
1696.8794	1695.8721	1695.8580	K.YKPQVNSSINDYIR.K
1718.9045	1717.8972	1717.8999	K.SPVNVNQSYSIKPGTK.L
1749.8965	1748.8892	1748.9131	K.SPVNVMQTYTVKPGTK.L
1765.8677	1764.8604	1764.9080	K.SPVNVMQTYTVKPGTK.L + Oxidation (M)
1794.8242	1793.8169	1793.8908	K.QEAGAVSGTGNQTFKATK.Q
1866.8675	1865.8602	1865.8445	K.NNYQNAFVHAFVDGDR.I
2001.9170	2000.9098	2000.9115	R.SHNYSYDQLYDLINX.Y
2019.0255	2018.0182	2018.0010	R.FINVEIVHTHDYASFA.R
2216.1376	2215.1304	2215.1273	R.IIETAPTDYLSWVGAVGNPR.F
2298.1750	2297.1677	2297.1652	K.NPTQNIISGTQVYQDPAIVQPK.T
2640.4100	2639.4027	2639.3806	K.AYLVDTAKPTPTPKPSTPTTNNK.L
2841.4854	2840.4781	2840.4556	K.VAPWGTQSTTPTTTPSKPTTSPKSTGK.L
3322.5774	3321.5701	3321.5120	K.TNTNVTNAGYSLVDEDDNSENQINPELIK.S

the *atl* mRNA was detected between U<sub>74</sub>-U<sub>85</sub> (SprC)/A<sub>+12</sub>-A<sub>+23</sub> (*atl* mRNA). Therefore, the capacity of a SprC mutant lacking nucleotides U78-U89 (SprC<sub>Δ78-89</sub>) to influence *atl* mRNA translation was analyzed. As expected and compared to SprC, SprC<sub>Δ78-89</sub> had an impaired ability to lower translation initiation onto the *atl* mRNA (Figure 2C). EMSA performed between SprC<sub>Δ78-89</sub> and the *atl* mRNA reinforces further these results by showing that complex formation is severely impaired (Figure 2D). Another SprC mutant lacking G55-G67 (SprC<sub>Δ55-67</sub>) was constructed, because it was predicted, based on SprC secondary structure, to destabilize helix H2, in turn possibly enhancing its downregulation of *atl* mRNA translation. Indeed, increasing amounts of SprC<sub>Δ55-67</sub> reduced the toeprint in a concentration-dependent manner, significantly more than SprC (Figure 2C), indicating that mutant SprC<sub>Δ55-67</sub> has increased regulatory activity onto the *atl* mRNA than SprC. As internal control for the toeprint assays, the putative interaction between SprC and the purified ribosomes was challenged experimentally by filter binding assays and Supplementary Figure S1A shows that whereas the *atl* mRNA associates with the ribosomes, SprC does not. Moreover, EMSA performed between labeled SprC and the tRNA<sup>fMet</sup> have not detected any interaction between the two RNAs (Supplementary Figure S1B). These data indicate that SprC does not interact with either ribosomes or tRNA<sup>fMet</sup>. Overall, the *atl* mRNA is a direct molecular target of SprC and the sRNA likely reduces its protein expression levels by preventing translation initiation, but the interaction between the two RNAs is elaborate and will need further structural investigations.

### Implementing an *S. aureus* internalization assay in human phagocytes


SprC lowers the expression of the major autolysin ATL. ATL has implications in cell wall turnover, cell separation,

division, autolysis, and mediates *S. aureus* internalization by endothelial cells (18,25). We hypothesized that SprC's regulation of ATL synthesis could influence bacterial uptake by the host's professional phagocytes. To test that assumption, an assay was implemented monitoring *S. aureus* uptake by human phagocytes, including THP1 monocytes and macrophages. Flow cytometric internalization assays were set up by using a THP1 monocyte cell line. The *S. aureus* Newman cells were labeled with FITC. The human THP1 cells were incubated with the bacteria. Various ratios between the human cells and the bacteria were assayed, and a 1:10 ratio was selected. Incubations were from 5 min to 3 h, after which the extracellular bacteria were removed by lysostaphin treatment. Phagocytosis was monitored by flow cytometry. The absence of any remaining extracellular microorganisms, after the lysostaphin treatment, was verified by microscopy (Figure 3A, panels 1 and 2) and confocal microscopy showed *S. aureus* internalization by the human host cells (Figure 3A, panel 3). Cytochalasin D, an actin depolymerizing agent, inhibits actin-dependent *S. aureus* uptake by the host cells (26). Cytochalasin was used as an inhibitor of host cell *S. aureus* uptake, providing evidence that the number of internalized bacteria reflects host cell uptake into the intracellular compartment. Increasing amounts of cytochalasin D drastically reduced the number of *S. aureus* cells present in the human macrophages (Figure 3B). It indicates that the number of internalized bacteria is dependent on uptake into the intracellular compartment, demonstrating phagocytosis in our assay.

### Atl facilitates *S. aureus* internalization by the human phagocytes

We analyzed the capacities of a *S. aureus* Newman *atl*-deficient mutant (a gift from Prof. J. O'Gara, Dublin, Ireland), a complemented strain with a plasmid expressing the protein (27) and an isogenic Newman strain to be internal-





**Figure 3.** Implementing an *S. aureus*-host cell phagocytosis assay showing that Atl facilitates *S. aureus* uptake by the human phagocytes. (A) Human THP1 cells are incubated for 1 h with FITC labeled *S. aureus* Newman cells (MOI 1:10). Coverslips are mounted with the 'Vectashield mounting medium' containing DAPI. The human cell nucleus is blue (DAPI) and the *S. aureus* cell wall is green (FITC). The extracellular bacteria were (panel 2), or not (panel 1), lysed with lysostaphin for 10 min. After the lysostaphin treatment, microscope imaging did not detect extracellular bacteria (compare panels 1 and 2). The bacteria were also viewed by confocal microscopy (panel 3). In panel 3, the *S. aureus* cells are stained green (FITC), the host cells nuclei are blue (DAPI) and the host cell membranes are gray, imaged by Differential Image Contrast (DIC). In panel 3, two orthogonal sections are presented, demonstrating *S. aureus* internalization. (B) Staphylococcal phagocytosis by human macrophages as evidenced by Cytochalasin D treatment. Cytochalasin D-treated THP1 macrophages were infected with *S. aureus* (Newman) for 2 h followed by adding gentamycin for 1 h to remove the extracellular bacteria. Infected THP1 macrophages without Cytochalasin D treatment served as internal positive controls. The data shown are the mean  $\pm$  SD of three independent experiments, each realized in triplicates. The data are considered highly significant for  $P$ -values  $\leq 0.01$  (\*\*). (C) The major autolysin ATL facilitates *S. aureus* internalization in human professional phagocytes. Amount of labeled THP1 cells after the internalization of FITC-labeled *S. aureus* Newman strains (1), Newman strain in the presence of pLI<sub>50atl</sub> (2), strain lacking *atl* expression (3) or  $\Delta atl$  Newman strain complemented with pLI<sub>50atl</sub> (4). FITC labeled *S. aureus* strains were incubated for 5 min, 1 or 3 h with the human THP1 monocytes (MOI 1:10). The cells were analyzed by flow cytometry. The data shown are the mean  $\pm$  SD of three independent experiments, each realized in triplicates. The data are considered significant for  $P$ -values  $< 0.05$  (\*), highly significant for  $P$ -values  $\leq 0.01$  (\*\*) and extremely significant for  $P$ -values  $\leq 0.001$  (\*\*\*)

ized by the human THP1 cells. The absence of *atl* mRNA expression in strain Newman  $\Delta atl$  was confirmed by qPCR, as well as its expression in the complemented strain Newman  $\Delta atl$ -*pLI<sub>50</sub> atl* (not shown). Compared to a Newman strain, flow cytometric internalization assays indicated that the  $\Delta atl$  mutation reduced the ability of the Newman strain to be internalized by the THP1 host cells by  $\sim 20\%$ . The effect was observed early, after 5 min incubation (Figure 3C). Compared to an isogenic *S. aureus* strain, the internalization of Newman  $\Delta atl$  by the human host cells was decreased and that reduction was reversed by *atl* complementation (Figure 3C). These experiments indicated that the ATL protein facilitates *S. aureus* internalization by human professional phagocytes and that its absence reduces uptake by host cells.

### SprC lowers internalization by human phagocytes and its absence increases *S. aureus* uptake

ATL protein facilitates *S. aureus* uptake by the host cells and SprC reduces Atl protein expression. To test if SprC influences *S. aureus* internalization by the host cells, phagocytosis of *S. aureus* strain Newman- $\Delta sprC$  by human monocytes was compared to an isogenic Newman strain. Host cell internalization of strain Newman  $\Delta sprC$  gradually increased over time, reaching a level  $\sim 40\%$  higher than for strain Newman (Figure 4). SprC was overexpressed from a low copy ( $\sim 20$ – $25$  copies per cell) pCN38 $\Omega sprC$  plasmid in which *sprC* was cloned with its endogenous promoter. Strains Newman-pCN38 and Newman-pCN38 $\Omega sprC$  had similar growth curves and Northern blots confirmed SprC overexpression in the latter strain (Figure 4). qPCR quantifications indicated a  $50 \pm 10$  fold increase in SprC expression levels in strain Newman pCN38 $\Omega sprC$  compared to the strain carrying an empty plasmid (not shown). The level of induction of SprC expression in strains with pCN38 $\Omega sprC$  reduced the amount of internalized bacteria by the human phagocytes by  $\sim 20\%$  (Figure 4A). When the *S. aureus* Newman cells were transformed with a high copy ( $\sim 300$ – $400$  copies per cell) pCN35 $\Omega sprC$  plasmid, SprC expression was significantly enhanced whereas bacterial growth was unaffected (Figure 4B). qPCR quantifications of SprC levels in strain Newman pCN35 $\Omega sprC$ , compared to the strain with an empty plasmid, indicated a  $500 \pm 50$  fold increase in SprC expression (not shown). Compared to Newman pCN35, the number of Newman pCN35 $\Omega sprC$  bacteria internalized by the human monocytes was reduced by  $\sim 40\%$  (Figure 4A). Inducing SprC expression reduces *S. aureus* uptake by the host cells and the effect increases with the amount of SprC produced.


The influence of SprC on *S. aureus* phagocytosis was also evaluated in human macrophages, whose primary roles are to ingest foreign particles and infectious microorganisms. Phagocytosis of *S. aureus* strain Newman- $\Delta sprC$  by PMA-induced THP1 macrophages was compared to an isogenic Newman strain. Host cell internalization of strain Newman- $\Delta sprC$  was significantly enhanced compared to strain Newman (Figure 5A). A *trans*-complemented Newman  $\Delta sprC$ -pCN38 $\Omega sprC$  strain was constructed. Northern blots confirmed the re-expression of SprC in strain Newman  $\Delta sprC$ -pCN38 $\Omega sprC$ , and its growth was identical

to that of the strain Newman- $\Delta sprC$ -pCN38 (Figure 5C). Conversely, the phagocytosis of a *trans*-complemented strain (Newman  $\Delta sprC$ -pCN38 $\Omega sprC$ ) was decreased compared to a Newman  $\Delta sprC$ -pCN38 strain. Interestingly, bacterial release from the THP1 macrophages, after 4 days, was significantly increased in the absence of the sRNA, and reduced in the *trans*-complemented strains (Figure 5B). Therefore, these observations suggest that the bacteria lacking SprC could possess higher virulence by a higher uptake and release from the immune host cells.


To provide experimental evidence about a link between the ATL and SprC regarding the *S. aureus* internalization phenotype, we purified the ATL protein and monitored its influence on phagocytosis of *S. aureus* strain Newman lacking *sprC*, in comparison with strain Newman (attempts to construct a  $\Delta sprC$ - $\Delta atl$  double mutant failed). Pre-incubation of the macrophages with a purified full-length ATL protein, dose-dependently reduced internalization of *S. aureus* bacteria lacking SprC, but has no or limited effects on *S. aureus* bacteria expressing SprC (Figure 5D). This result suggests that the effect of SprC on phagocytosis is mediated, at least in part, by its regulatory action onto ATL.

### SprC attenuates *S. aureus* virulence and its induction lowers bacterial spread


*S. aureus* survives and multiplies within several host cells including endothelial and epithelial cells, keratinocytes, fibroblasts and osteoclasts (28). Intracellular *S. aureus* uses human phagocytes, especially the neutrophils, to travel and infect distant sites (29). Bacteria lacking *sprC* may use the host phagocytes for dissemination and multiplication into the colonized host, in turn providing a significant advantage during infection and spread into the infected hosts. To assay that hypothesis, the implication of SprC expression was tested in a mouse systemic infection model, as performed for SprD (15). The virulence of strain Newman- $\Delta sprC$  was significantly and reproducibly enhanced, with half the animals already deceased at day 9 of infection (Figure 6A), five days earlier than what is observed with strain Newman. Compared to strain Newman- $\Delta sprC$ -pCN38, the virulence of the *trans*-complemented strain Newman  $\Delta sprC$ -pCN38 $\Omega sprC$  was partially restored (Figure 6B). After day 6 of infection, the *in vivo* persistence of plasmid pCN38 $\Omega sprC$  in the Newman  $\Delta sprC$ -pCN38 $\Omega sprC$  complemented strain was verified in selected colonies obtained from mice kidney homogenates. All the selected colonies retained chloramphenicol resistance, a specific marker of pCN38. In a different intravenous infection experiment, the animals were sacrificed at day 4, the kidneys of groups of five mice inoculated with strains Newman, Newman  $\Delta sprC$ , Newman  $\Delta sprC$ -pCN38 and the *trans*-complemented Newman  $\Delta sprC$ -pCN38 $\Omega sprC$  strain were collected and viable bacteria counted. Kidneys of mice inoculated with the  $\Delta sprC$  mutant are swollen and displayed mottled discoloration with numerous abscesses, whereas those of mice inoculated with strain Newman are homogeneously red-brown with only a few abscesses (Figure 6C). Kidneys of mice infected with the SprC-complemented strains display homogenous coloration with very few abscesses (Figure 6C).



**Figure 4.** SprC reduces *S. aureus* internalization by human monocytes and its absence augments phagocytosis. **(A)** Percentage of THP1 cells labeled with FITC after *S. aureus* internalization. FITC labeled *S. aureus* Newman and Newman- $\Delta$ sprC, Newman-pCN38 and Newman-pCN38 $\Delta$ sprC, Newman-pCN35 and Newman-pCN35 $\Delta$ sprC were incubated with the human monocytes (MOI 1:10) for the indicated times. The cells were analyzed by flow cytometry. For a direct comparison of the *S. aureus* strains, we set up the labeling of control strains 'Newman', 'Newman-pCN35' and 'Newman-pCN38' arbitrarily at '10'. The data presented and the error bars indicated are the mean  $\pm$  SD derived from three independent experiments ( $p^* < 0.025$ ). **(B)** Lacking or stimulating SprC expression *in vivo* does not impact *S. aureus* growth. Monitoring bacterial growth and SprC expression levels, by Northern blots (OD<sub>600nm</sub> = 2), in *S. aureus* strains Newman pCN35 (blue) and Newman-pCN35 $\Delta$ sprC (pink). The 5S rRNAs are the loading controls. The data presented are the mean  $\pm$  SD of three independent experiments realized in triplicates. The data are considered significant for  $P$ -values  $< 0.025$  (\*).



**Figure 5.** SprC reduces *S. aureus* internalization by human macrophages and its absence augments phagocytosis and bacterial release from the host cells. (A) Number of *S. aureus* cells (CFU) after internalization. Newman, Newman- $\Delta sprC$ , Newman- $\Delta sprC$  pCN38 and Newman- $\Delta sprC$  pCN38 $\Delta sprC$  cells were incubated with the THP1 macrophages (MOI 1:25) for 2 h. The non-phagocytosed bacteria were killed by culturing in medium containing 50  $\mu$ g/ml gentamycin for 24 h. The medium was then replaced with fresh media for up to 4 days. (B) After 4 days, colony counts correspond to the bacteria that were released by the human macrophages. The data presented are the mean  $\pm$  SD of three independent experiments realized in triplicates. The data are considered highly significant for  $P$ -values  $\leq 0.01$  (\*\*). (C) Monitoring bacterial growth and SprC expression levels, by Northern blots (OD<sub>600nm</sub> = 2), in *S. aureus* strains Newman  $\Delta sprC$ -pCN38 (pink) and Newman  $\Delta sprC$ -pCN38 $\Delta sprC$  (blue). The 5S rRNAs are the loading controls. Each blot presented is from identical experiments. (D) Inhibition of *S. aureus* strain Newman  $\Delta sprC$  phagocytosis by the THP1 macrophages by adding increasing concentrations of purified ATL protein (right panel) whereas exogenous ATL has limited, if any, effects on *S. aureus* strain Newman internalization (left panel).



**Figure 6.** SprC attenuates the virulence and spread of a *S. aureus* clinical isolate on infected mice. **(A)** Survival probability plots (Kaplan-Meier) of mice infected either with *S. aureus* Newman (blue,  $5.10^7$  cfu per mouse) or isogenic *S. aureus* Newman- $\Delta sprC$  (red;  $5.10^7$  cfu);  $0.05 < P\text{-value} < 0.1$ . Groups of 10 'six to eight-weeks old' Swiss mice were inoculated intravenously with  $5.10^9$  bacteria and monitored daily for 2 weeks. The Mantel-Haenszel test  $P$ -value is between 0.01 and 0.05. The results are representative of three independent experiments representing 30 mice per strain. **(B)** Survival probability plots (Kaplan-Meier) of mice infected either with *S. aureus* Newman- $\Delta sprC$ pcN38 (blue;  $5.10^7$  cfu) or *S. aureus* Newman- $\Delta sprC$ pcN38 $\Omega sprC$  (red,  $5.10^7$  cfu per mouse); The Mantel-Haenszel test  $P$ -value is lower than 0.01. Results are representative of three independent experiments representing 30 mice per strain. **(C)** Recovery of *S. aureus* from the kidneys of infected mice four days after bacterial challenge. Groups of 5 mice were inoculated intravenously with the indicated strains. Each individual is indicated by a circle symbol, with mean bacterial titers as red lines. The Mann-Whitney test  $P$ -value is between 0.01 and 0.05. The red line represents the mean value of 5 mice. Bottom: Macroscopic aspects of the recovered kidneys after intravenous infection with the respective *S. aureus* strains.

Results of the macroscopic observation are confirmed, in the same experiment, by viable bacteria counts per kidney pairs for the different strains (Figure 6C). Comparing the viable bacteria number per kidney in strains Newman versus Newman- $\Delta sprC$ , and Newman- $\Delta sprC$ -pCN38 versus Newman- $\Delta sprC$ -pCN38 $\Omega sprC$ , using the Mann-Whitney U test, indicates a significant *P*-value ( $<0.05$ ). Altogether, these results indicated that SprC has a negative impact on the virulence of a *S. aureus* human isolate in an animal infection model. SprC is therefore a virulence attenuator, reducing bacterial spread into the colonized mice.

### SprC is detrimental for *S. aureus* resistance in the presence of a sublethal oxidative stress

Since SprC has a negative impact on virulence and host cell internalization, the sRNA might also influence *S. aureus* intracellular survival and persistence. In the presence of a sublethal oxidative stress triggered by hydrogen peroxide (5 mM), strain Newman  $\Delta sprC$  grew better than its isogenic control strain (Figure 7A). The *trans*-complemented strain Newman  $\Delta sprC$ -pCN38 $\Omega sprC$  has a restored growth phenotype in the presence of hydrogen peroxide (Figure 7B). In the presence of hydrogen peroxide, inducing SprC expression substantially (Figure 7C) or moderately (Figure 7D) delayed *S. aureus* growth, with respect to their internal controls without sRNA induction. These data indicate that, when *S. aureus* adapts to oxidative stress, the absence of *sprC* is beneficial whereas inducing SprC expression is prejudicial for growth, in agreement with the experiments performed at the cellular and animal levels.


### SprC expression decreases after *S. aureus* host cell internalization

Since the absence of SprC facilitates *S. aureus* host cell internalization (Figures 4 and 5), virulence (Figure 6) and alleviates resistance against an oxidant (Figure 7), we conjectured that SprC expression might be diminished after bacterial uptake by the host cells. To test this hypothesis, total eukaryotic and prokaryotic RNAs were extracted from human THP1 cells infected with labeled *S. aureus* strain and deprived of extracellular bacteria Newman after 5 min, 1 h and 3 h of incubation, according to the experimental set up described above. SprC expression levels were monitored by qPCR. Within the infected host cells, SprC expression is detected early and decreases ~4-fold after 1 h and ~10-fold after 3 h (Figure 7E). As an internal control, the expression of another *S. aureus* sRNA, transfer-messenger RNA (tmRNA), responsible of ribosome rescue and *trans*-translation (30) was monitored during host cell phagocytosis. At the three time points after *S. aureus* internalization, tmRNA expression is maintained relatively stable over time (Figure 7E). The steady state levels of the *hu* mRNA, from 5 min to 3 h, were stable, indicating that the internalized *S. aureus* cells are alive and transcriptionally active. The lower expression of SprC within the ingested staphylococci could increase their resistance to oxidative killing by the immune cells, in turn promoting their dissemination into the colonized host.

## DISCUSSION

We report the case of a regulatory RNA expressed from the accessory genome of a major bacterial pathogen, *S. aureus*, that reduces virulence and host immune cell phagocytosis. When SprC is not expressed, the bacteria are internalized more, resist better to an oxidative burst, are released further by the human phagocytes and possess increased virulence in an animal infection model. SprC expression is detrimental for bacterial spread into the colonized organisms, induces a disadvantage for intracellular entry and resistance against an oxidative environment. This may explain why its expression is turned off after host cell internalization. Another sRNA expressed from the *S. aureus* core genome, RsaA, is also a virulence suppressor that favors chronic infection (16). Interestingly, whereas SprC lowers both the host cell phagocytosis and the oxidative stress resistance, RsaA renders the bacteria more sensitive to opsonophagocytosis by the host PMNs. These two sRNAs, expressed from the core (RsaA) and accessory (SprC) genome, attenuate staphylococcal virulence by distinct mechanisms. Why does *S. aureus* express sRNAs exerting negative influences on pathogenicity? *sprC* is detected in numerous *S. aureus* clinical strains but its expression levels has not been monitored yet and we also do not know if its negative impact on virulence can be extrapolated to many clinical isolates. Nevertheless, recent results in the lab performed on clinical strains isolated from thirty patients with bloodstream infections indicate that 30% of the strains lack *sprC* whereas only 20% of the strains isolated from a set of thirty asymptomatic colonized individuals lack *sprC*. A negative selection pressure against *sprC* may operate faster in the clinical strains than for those present in the asymptomatic carriers, but this result should be confirmed on a larger set of individuals.

sRNAs impacting host cell entry and invasion were reported in several bacteria. The PI-encoded IsrM sRNA is required for *Salmonella* invasion of epithelial cells, intracellular replication inside macrophages, virulence and colonization in mice (31). Also, the expression of the AfaD invasins that mediate entry of *E. coli* clinical isolates into the host cells from various tissues is controlled and reduced by the AfaR antisense sRNA (32). As for the *E. coli* AfaR, SprC protects the bacteria against their engulfment by the human host cells. Neutrophils and monocytes struggle to eradicate many invading pathogens, including *S. aureus* (33). In the Gram positive bacterium *Listeria monocytogenes*, several sRNAs are specifically expressed when the bacteria are within the macrophages (34), but their implications for bacterial survival are unknown. In the Gram negative *Salmonella enterica* serovar Typhi, two sRNAs, RfrA and RfrB, are also required for optimal bacterial intracellular replication in macrophages (35). The expression of RNAIII, the effector of the *agr* quorum-sensing system in *S. aureus*, is also modified after ingestion of *S. aureus* clinical strain USA300 by the human neutrophils but, in that case, its expression rapidly increases to produce  $\alpha$ -hemolysin and, in turn, to trigger PMN lysis (36). We monitored RNAIII expression levels, by qPCR, on the total eukaryotic and prokaryotic extracted RNAs, during human THP1 infection by labeled *S. aureus* strain Newman. After infection, the expression of RNAIII reproducibly increases



**Figure 7.** SprC reduces *S. aureus* resistance toward hydrogen peroxide and its expression level decreases in internalized bacteria. Growth curves of Newman, Newman- $\Delta sprC$  (A), Newman- $\Delta sprC$ -pCN38 and Newman- $\Delta sprC$ -pCN38 $\Omega sprC$  (B), Newman-pCN35, 'Newman-pCN35 $\Omega sprC$ ' strains (C), 'Newman-pCN38' and 'Newman-pCN38 $\Omega sprC$ ' (D), after exposure to 5 mM hydrogen peroxide ( $H_2O_2$ ). Optical density was measured using the spectrophotometer Biotek Synergy from 0 for 24 h. Growth curves are representative of three experiments. (E), SprC expression levels decrease in bacteria internalized by human monocytes. Monitoring the expression levels of SprC (dark gray) and of tmRNA (light gray) by qPCR during phagocytosis of *S. aureus* wild-type strain Newman. The bacteria were labeled by FITC, incubated with the human monocytes (MOI 1:10) for the indicated periods of times and total RNAs extracted. Using the comparative Ct method, the amount of sRNAs was normalized against the expression of the *hu* reference gene and referred to the internalized bacteria after 5 min of phagocytosis. The data presented are the mean  $\pm$  SD of three independent experiments realized in triplicates. The data are considered significant for  $P$ -values  $<0.05$  (\*) and extremely significant for  $P$ -values  $\leq 0.001$  (\*\*\*)

(6±1-fold) compared to the non-internalized bacteria (not shown). Therefore, in clinical strain Newman, the expression of another *S. aureus* sRNA is modified upon host cell uptake for survival and escape immune clearance. Is there a functional link between SprC and RNAlII? Preliminary experiments have monitored, by Northern blots, the RNAlII levels during *S. aureus* growth in strains lacking or overexpressing SprC. At three time points during growth, RNAlII levels were not influenced by the presence/absence of SprC (not shown). These recent examples, including our findings, indicate that once bacterial pathogens are internalized, the expression of dedicated sRNAs and various toxins can be required for their intracellular persistence and growths.

The human phagocytes are the first line of host defenses against the invading pathogens. Intracellular bacterial persistence includes 'phagosome-lysosome' fusion inhibition, survival inside the phagolysosomes and cytoplasm escape (37). When the bacteria survive, multiply and are released from the host cells, phagocytosis becomes an advantage for colonization and spread. Within the host phagocytes, *S. aureus* cells lacking SprC possess a higher ability to disseminate and spread, ultimately stimulating the overall infectious process. *S. aureus* phagocytosis by neutrophils induce global changes in gene expression, including proteins involved in resistance to oxidants (9). In *S. aureus*, the expression of many protein-encoding genes, including virulence genes, is modified in response to an oxidative stress (38,39). When *S. aureus* is phagocytosed, it faces and resists the host defenses and resides in phagosomes containing antimicrobial peptides, proteolytic enzymes and reactive oxygen intermediates. The aim of the reactive oxygen species secreted by the host cells is to destroy the engulfed bacteria. The increased virulence of bacteria lacking SprC could be linked to its higher survival rate in an oxidative environment such as the phagolysosome. It suggests a tight coupling between resistance against oxidants and bacterial virulence, exemplified here by SprC. Future studies should address if SprC is involved in *S. aureus* phagosomal escape (40).

We identified one direct molecular target of SprC whose expression is down-regulated during translation initiation, by antisense pairings, the ATL staphylococcal autolysin. Many sRNAs are multifunctional and it might also be the case of SprC, having additional regulatory functions involved in *S. aureus* fitness with its environment. The interaction between SprC and the *atl* mRNA is weak and complex, probably implying the existence of additional RNA and/or protein associates involved in the interaction. This is of noticeable interest in the *S. aureus* sRNA field because, until now, there are no facilitator/chaperone involved in RNA-RNA interactions characterized in this bacterium. In addition to its positive implication in host cell phagocytosis, ATL has activities in cell division, autolysis and biofilm formation (41), suggesting that SprC may also influence these bacterial functions. Preliminary experiments reported here suggest that SprC influences host phagocytosis, at least in part, by its control of ATL expression. The functional link between SprC and Atl regarding phagocytosis could therefore be established. Strain  $\Delta$ *sprC* expresses more ATL at the bacterial surface, compared to wild-type (Figure 1E), consequently predicted to interact more efficiently with the ATL receptors located at the surface of the human phagocytes,

therefore increasing bacterial phagocytosis. When the ATL protein is provided externally, it binds to and blocks some of the human phagocytes receptors, subsequently preventing bacterial uptake via these ATL receptors. Thus, the progressive decrease of internalized staphylococci lacking *sprC*, when the ATL is provided externally, may be rationalized by the above arguments. This is probably not observed in the case of the wild-type cells because they express lower amounts of ATL at the bacterial surface (Figure 1E) and, therefore, may be less affected by the blocking of the ATL receptors from the human phagocytes via the 'externally' provided ATL. The physiological associations and implications between the *S. aureus* phagocytosis, SprC and ATL 'triumvirate' are currently being addressed experimentally.

## SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

## ACKNOWLEDGEMENT

We thank Dr P. Ame-Thomas (UMR U917, Rennes University) for her advices and help in THP1 cell culture and flow cytometry and Dr S. Dutertre (UMS 3480– US018 Biosit Ibis Plateform of Microscopy, Rennes Imaging Center MRic-Photonics) for her help with the microscopes and data collection. We also thank M1 student S. Raynaud for his help in the ATL purification and cell culture experiments and Dr M. Sassi for the SprC sequence alignments. We also thank the colleagues from the lab for their comments on the manuscript.

## FUNDING

Agence Nationale pour la Recherche [ANR-09-MIEN-030–01]; Inserm; French Department of Research and Education [to B.F.]. Funding for open access charge: Inserm; [to B.F.].

*Conflict of interest statement.* None declared.

## REFERENCES

- Hossain, H., Tchatalbachev, S. and Chakraborty, T. (2006) Host gene expression profiling in pathogen-host interactions. *Curr. Opin. Immunol.*, **18**, 422–429.
- Bestebroer, J., De Haas, C.J. and Van Strijp, J.A. (2010) How microorganisms avoid phagocyte attraction. *FEMS Microbiol. Rev.*, **34**, 395–414.
- Shimada, T., Park, B.G., Wolf, A.J., Brikos, C., Goodridge, H.S., Becker, C.A., Reyes, C.N., Miao, E.A., Aderem, A., Gotz, F. *et al.* (2010) Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1 $\beta$  secretion. *Cell Host Microbe*, **7**, 38–49.
- Zeconi, A. and Scali, F. (2013) Staphylococcus aureus virulence factors in evasion from innate immune defenses in human and animal diseases. *Immunol. Lett.*, **150**, 12–22.
- Broker, B.M., Holtfreter, S. and Bekeredjian-Ding, I. (2014) Immune control of Staphylococcus aureus - regulation and counter-regulation of the adaptive immune response. *Int. J. Med. Microbiol.*, **304**, 204–214.
- Loffler, B., Tuchscher, L., Niemann, S. and Peters, G. (2014) Staphylococcus aureus persistence in non-professional phagocytes. *Int. J. Med. Microbiol.*, **304**, 170–176.
- Matussek, A., Strindhall, J., Stark, L., Rohde, M., Geffers, R., Buer, J., Kihlstrom, E., Lindgren, P.E. and Lofgren, S. (2005) Infection of



- human endothelial cells with *Staphylococcus aureus* induces transcription of genes encoding an innate immunity response. *Scand. J. Immunol.*, **61**, 536–544.
8. Vriesema, A.J., Beekhuizen, H., Hamdi, M., Soufan, A., Lammers, A., Willekens, B., Bakker, O., Welten, A.G., Veltrop, M.H., van De Gevel, J.S. *et al.* (2000) Altered gene expression in *Staphylococcus aureus* upon interaction with human endothelial cells. *Infect. Immun.*, **68**, 1765–1772.
  9. Voyich, J.M., Braughton, K.R., Sturdevant, D.E., Whitney, A.R., Said-Salim, B., Porcella, S.F., Long, R.D., Dorward, D.W., Gardner, D.J., Kreiswirth, B.N. *et al.* (2005) Insights into mechanisms used by *Staphylococcus aureus* to avoid destruction by human neutrophils. *J. Immunol.*, **175**, 3907–3919.
  10. Garzoni, C., Francois, P., Huyghe, A., Couzinet, S., Tapparel, C., Charbonnier, Y., Renzoni, A., Lucchini, S., Lew, D.P., Vaudaux, P. *et al.* (2007) A global view of *Staphylococcus aureus* whole genome expression upon internalization in human epithelial cells. *BMC Genomics*, **8**, 171.
  11. Guillet, J., Hallier, M. and Felden, B. (2013) Emerging functions for the *Staphylococcus aureus* RNome. *PLoS Pathog.*, **9**, e1003767.
  12. Fechter, P., Caldeleri, I., Lioliou, E. and Romby, P. (2014) Novel aspects of RNA regulation in *Staphylococcus aureus*. *FEBS Lett.*, **588**, 2523–2529.
  13. Sassi, M., Augagneur, Y., Mauro, T., Ivain, L., Chabelskaya, S., Hallier, M., Sallou, O. and Felden, B. (2015) SRD: a *Staphylococcus* regulatory RNA database. *RNA*, **21**, 1005–1017.
  14. Pichon, C. and Felden, B. (2005) Small RNA genes expressed from *Staphylococcus aureus* genomic and pathogenicity islands with specific expression among pathogenic strains. *Proc. Natl. Acad. Sci. U.S.A.*, **102**, 14249–14254.
  15. Chabelskaya, S., Gaillot, O. and Felden, B. (2010) A *Staphylococcus aureus* small RNA is required for bacterial virulence and regulates the expression of an immune-evasion molecule. *PLoS Pathog.*, **6**, e1000927.
  16. Romilly, C., Lays, C., Tomasini, A., Caldeleri, I., Benito, Y., Hammann, P., Geissmann, T., Boisset, S., Romby, P. and Vandenesch, F. (2014) A non-coding RNA promotes bacterial persistence and decreases virulence by regulating a regulator in *Staphylococcus aureus*. *PLoS Pathog.*, **10**, e1003979.
  17. Eyraud, A., Tattevin, P., Chabelskaya, S. and Felden, B. (2014) A small RNA controls a protein regulator involved in antibiotic resistance in *Staphylococcus aureus*. *Nucleic Acids Res.*, **42**, 4892–4905.
  18. Hirschhausen, N., Schlesier, T., Schmidt, M.A., Gotz, F., Peters, G. and Heilmann, C. (2010) A novel staphylococcal internalization mechanism involves the major autolysin Atl and heat shock cognate protein Hsc70 as host cell receptor. *Cell. Microbiol.*, **12**, 1746–1764.
  19. Bruckner, R. (1997) Gene replacement in *Staphylococcus carnosus* and *Staphylococcus xylosus*. *FEMS Microbiol. Lett.*, **151**, 1–8.
  20. MacCallum, A., Hardy, S.P. and Everest, P.H. (2005) *Campylobacter jejuni* inhibits the absorptive transport functions of Caco-2 cells and disrupts cellular tight junctions. *Microbiology*, **151**, 2451–2458.
  21. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, **227**, 680–685.
  22. Komatsuzawa, H., Sugai, M., Nakashima, S., Yamada, S., Matsumoto, A., Oshida, T. and Suginaka, H. (1997) Subcellular localization of the major autolysin, ATL and its processed proteins in *Staphylococcus aureus*. *Microbiol. Immunol.*, **41**, 469–479.
  23. Oshida, T., Sugai, M., Komatsuzawa, H., Hong, Y.M., Suginaka, H. and Tomasz, A. (1995) A *Staphylococcus aureus* autolysin that has an N-acetylmuramoyl-L-alanine amidase domain and an endo-beta-N-acetylglucosaminidase domain: cloning, sequence analysis, and characterization. *Proc. Natl. Acad. Sci. U.S.A.*, **92**, 285–289.
  24. Zuker, M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.*, **31**, 3406–3415.
  25. Vollmer, W., Joris, B., Charlier, P. and Foster, S. (2008) Bacterial peptidoglycan (murein) hydrolases. *FEMS Microbiol. Rev.*, **32**, 259–286.
  26. Sinha, B., Francois, P.P., Nusse, O., Foti, M., Hartford, O.M., Vaudaux, P., Foster, T.J., Lew, D.P., Herrmann, M. and Krause, K.H. (1999) Fibronectin-binding protein acts as *Staphylococcus aureus* invasin via fibronectin bridging to integrin alpha5beta1. *Cell. Microbiol.*, **1**, 101–117.
  27. Houston, P., Rowe, S.E., Pozzi, C., Waters, E.M. and O’Gara, J.P. (2011) Essential role for the major autolysin in the fibronectin-binding protein-mediated *Staphylococcus aureus* biofilm phenotype. *Infect. Immunol.*, **79**, 1153–1165.
  28. Garzoni, C. and Kelley, W.L. (2009) *Staphylococcus aureus*: new evidence for intracellular persistence. *Trends Microbiol.*, **17**, 59–65.
  29. Thwaites, G.E., Edgeworth, J.D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Torok, M.E., Walker, S., Wertheim, H.F., Wilson, P. and Llewellyn, M.J. (2011) Clinical management of *Staphylococcus aureus* bacteraemia. *Lancet Infect. Dis.*, **11**, 208–222.
  30. Janssen, B.D. and Hayes, C.S. (2012) The tmRNA ribosome-rescue system. *Adv. Protein Chem. Struct. Biol.*, **86**, 151–191.
  31. Gong, H., Vu, G.P., Bai, Y., Chan, E., Wu, R., Yang, E., Liu, F. and Lu, S. (2011) A *Salmonella* small non-coding RNA facilitates bacterial invasion and intracellular replication by modulating the expression of virulence factors. *PLoS Pathog.*, **7**, e1002120.
  32. Pichon, C., du Merle, L., Lequeutre, I. and Le Bouguenec, C. (2013) The AfaR small RNA controls expression of the AfaD-VIII invasin in pathogenic *Escherichia coli* strains. *Nucleic Acids Res.*, **41**, 5469–5482.
  33. Mosser, D.M. and Edwards, J.P. (2008) Exploring the full spectrum of macrophage activation. *Nat. Rev. Immunol.*, **8**, 958–969.
  34. Mraheil, M.A., Billion, A., Mohamed, W., Mukherjee, K., Kuenne, C., Pischmarov, J., Krawitz, C., Retey, J., Hartsch, T., Chakraborty, T. *et al.* (2011) The intracellular sRNA transcriptome of *Listeria monocytogenes* during growth in macrophages. *Nucleic Acids Res.*, **39**, 4235–4248.
  35. Leclerc, J.M., Dozois, C.M. and Daigle, F. (2013) Role of the *Salmonella enterica* serovar Typhi Fur regulator and small RNAs RfrA and RfrB in iron homeostasis and interaction with host cells. *Microbiology*, **159**, 591–602.
  36. Pang, Y.Y., Schwartz, J., Thoendel, M., Ackermann, L.W., Horswill, A.R. and Nauseef, W.M. (2010) agr-Dependent interactions of *Staphylococcus aureus* USA300 with human polymorphonuclear neutrophils. *J. Innate Immunol.*, **2**, 546–559.
  37. Urban, C.F., Lourido, S. and Zychlinsky, A. (2006) How do microbes evade neutrophil killing? *Cell. Microbiol.*, **8**, 1687–1696.
  38. Chang, W., Small, D.A., Toghrol, F. and Bentley, W.E. (2006) Global transcriptome analysis of *Staphylococcus aureus* response to hydrogen peroxide. *J. Bacteriol.*, **188**, 1648–1659.
  39. Lee, L.Y., Liang, X., Hook, M. and Brown, E.L. (2004) Identification and characterization of the C3 binding domain of the *Staphylococcus aureus* extracellular fibrinogen-binding protein (Efb). *J. Biol. Chem.*, **279**, 50710–50716.
  40. Fraunholz, M. and Sinha, B. (2012) Intracellular *Staphylococcus aureus*: live-in and let die. *Front. Cell Infect. Microbiol.*, **2**, 43.
  41. Bose, J.L., Lehman, M.K., Fey, P.D. and Bayles, K.W. (2012) Contribution of the *Staphylococcus aureus* Atl AM and GL murein hydrolase activities in cell division, autolysis, and biofilm formation. *PLoS One*, **7**, e42244.